CASI Pharmaceuticals, Inc. filed a Form D with the Securities and Exchange Commission on 2026-04-28.
CASI Pharmaceuticals, Inc. filed a Form D notice of an exempt securities offering with the SEC on April 28, 2026. CASI Pharmaceuticals, Inc. trades on OTC as CASIF; it was formerly CASI Pharmaceuticals Holdings, Inc. The filing reports $5M sold. Its industry group is Pharmaceuticals. It names Wei-Wu He (Chairman to the Board), Zhenbo Su (Director), Thomas Folinsbee (Director) (SEC Form D, April 28, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like CASI Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-04-28 · the record
Pitching, partnering or investing alongside them? See who really runs and owns CASI Pharmaceuticals, Inc.
Free to see. No signup.
More on the people and the money behind CASI Pharmaceuticals, Inc., from the filings we hold.
Pharmaceuticals raises filed within 90 days of this one, largest first.
Get an email when CASI Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when CASI Pharmaceuticals, Inc. raises, hires or launches. No email unless you switch it on.
Watch CASI Pharmaceuticals, Inc. →Get the full cited report on CASI Pharmaceuticals, Inc.
What the filing shows about CASI Pharmaceuticals, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on CASI Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives CASI Pharmaceuticals, Inc.'s address as 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District, Beijing, F4 100025.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for CASI Pharmaceuticals, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on CASI Pharmaceuticals, Inc. See pricing
CASI Pharmaceuticals, Inc. is a registered filer with the SEC (CIK 1962738) and has filed since 2024-07-15. 5 filings are on record, the latest on 2026-04-28.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
CASI Pharmaceuticals, Inc.'s Form D of 2026-04-28 names Wei-Wu He, Zhenbo Su, Thomas Folinsbee and 9 more as its officers, directors or promoters.
Its new offerings report $35M sold across 5 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week. The dot is this raise, $5M, on the same scale — one filing against the whole group's total, so it sits low by construction.
On the filing as: Director.
Wei-Wu He is named as Chairman to the Board on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 April 2026, one of 12 people that filing names.
Zhenbo Su is named as Director on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 April 2026, one of 12 people that filing names.
Thomas Folinsbee is named as Director on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 April 2026, one of 12 people that filing names.
Alexander Wu is named as Director on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 April 2026, one of 12 people that filing names.
Xuebo Zeng is named as Director on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 April 2026, one of 12 people that filing names.
On the filing as: Executive Officer.
Wei Gao is named as General Counsel on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 April 2026, one of 12 people that filing names.
On the filing as: Executive Officer.
Kun Qian is named as Global Controller on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 April 2026, one of 12 people that filing names.
On the filing as: Executive Officer.
Chunhua Wang is named as Chief Operating Officer on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 April 2026, one of 12 people that filing names.
On the filing as: Executive Officer.
Hai Huang is named as Global Chief Commercial Officer on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 April 2026, one of 12 people that filing names.
On the filing as: Executive Officer.
Wei (Larry) Zhang is named as Vice President on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 April 2026, one of 12 people that filing names.
James Huang is named as Director on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 April 2026, one of 12 people that filing names.
Barbara Krebs-Pohl is named as Director on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 April 2026, one of 12 people that filing names.
12 people named on the filing — 5 holding an executive role and 7 as directors only.
Named as of the 2026-04-28 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about CASI Pharmaceuticals, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on CASI Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on CASI Pharmaceuticals, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist CASI Pharmaceuticals, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind CASI Pharmaceuticals, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for CASI Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/casi-pharmaceuticals-inc-form-d-26000004